Subscribe

Publications Update

LEAP-001: Pembro/Lenvima vs. Carbo/Taxol in Advanced/Recurrent Endometrial Cancer

First-line lenvatinib plus pembrolizumab did not significantly improve PFS or OS compared to chemotherapy in mismatch repair-proficient (pMMR) advanced endometrial cancer. Toxicity was higher in the experimental arm but manageable. dMMR exploratory analysis shows promise in this subgroup.

Publications Update # 82

Book recommendation - Get It Done by Ayelet Fishbach, MITO-18 trial summary and discussion points, NEJM paper - BALANCE trial, Trial flashback - road to carboplatin and taxol video (5 mins)

Publications Update # 81

Video summary of CHIPOR trial, study summary of CHIPOR trial

Publications Update # 80

Finding time to exercise, Management of STIC, NADINA trial in advanced melanoma, Final OS Keynote A-18, and overtreatment of locally advanced cervical cancer treatment prior to OUTBACK publication

Publications Update # 79

Strategies to overcome workaholism, prevent surgical site infections, and conduct the STOP-IT trial and BALANCE trial to reduce antibiotic duration.

Publications Update # 78

Medicine is Difficult article, discussion of interlace trial and PRIMA final survival data

Publications Update # 77

Living Room - Podcast Episode from Love+Radio, Keynote B21 trial and a video discussion of the trial and Compassion 16 trial in cervical cancer

Publications Update # 76

Focused Topic: Gestational Trophoblastic Neoplasia.

Publications Update # 75

Anthropocene Reviewed Podcast, tryanny of non-inferiority trials and a mini-tutorial on non-inferiority trials, GY-005 results, ENGOT-OV41 ANITA trial

Publications Update # 74

FIGO 2023 staging system for endometrial cancer - a deep dive.